Resonate: A Program to Improve Access to Genetic Testing and Genetic Counseling for Eligible Individuals with Auditory Neuropathy
Sep 22, 2021
Webinar information
Date: October 20, 2021
Time: 9:00 AM PST / 12:00 PM EST
Duration: 1 hour
C.E.U: -
Speaker: Kim Gall, Katie Nelson, Michael McKenna

Date: October 20, 2021
Time: 9:00 AM PST / 12:00 PM EST

Presented by Blueprint Genetics in collaboration with Akouos and InformedDNA.

The Resonate™ Program provides genetic testing and optional genetic counseling to eligible individuals of any age with a clinical diagnosis of auditory neuropathy, or a medical history consistent with auditory neuropathy, at no cost to participants, their insurance, or their healthcare providers. The program is available in the United States, and is sponsored by Akouos, Inc. Genetic testing is performed by Blueprint Genetics, and optional genetic counseling to review the results is available through InformedDNA.

In this webinar, we will provide an overview of the program, including the 239-gene Resonate Panel, optional genetic counseling services available to participants, and the informed consent and data sharing policies. We will also review data that highlights the diagnostic potential of including difficult-to-sequence genes, mitochondrial DNA sequencing, and pathogenic deep intronic variants.

This webinar is presented by Kim Gall, MSc., CGC, Senior Manager of Genomic Services from Blueprint Genetics, Katie Nelson, MS., CGC, Senior Clinical Genetic Counselor from InformedDNA, and Michael McKenna, MD., Chief Medical Officer and Co-Founder from Akouos.

Webinar objectives:

  • Introduce the Resonate Program and describe what makes it an excellent choice for eligible individuals with auditory neuropathy
  • Describe the Blueprint Genetics Resonate Panel
  • Outline informed consent and data sharing policies of the Resonate Program
  • Provide an overview of the optional genetic counseling services available in the United States



Kim Gall

Kim Gall, M.Sc., CGC, is Senior Manager of Genomic Services at Blueprint Genetics. She received a Bachelor of Science with Honours in Human Genetics from the University of Western Ontario and a Master of Science in Genetic Counselling from the University of British Columbia. She is certified by the American Board of Genetic Counselors. Ms. Gall worked in a variety of clinical and laboratory settings across Canada before accepting a position as clinical liaison at Blueprint Genetics in 2017.

Katie Nelson

Katie Nelson, MS, CGC, is Senior Clinical Genetic Counselor at InformedDNA. She has been a certified genetic counselor since 2007 and holds an MS in genetic counseling from Northwestern University. Ms. Nelson provides clinical genetic counseling services across multiple specialties, including hereditary forms of hearing loss. She has a specific research interest in genetic forms of sensorineural hearing loss.

Michael McKenna

Michael J. McKenna, MD, is Chief Medical Officer and Co-Founder of Akouos. He is a world-renowned neurotologist with expertise in translational inner ear drug delivery research. For the past 15 years, Dr McKenna led efforts to establish inner ear drug delivery systems to enable the development of hearing restoration therapies. Prior to founding Akouos, he held the Joseph B. Nadol, Jr. Chair and was the director of the Division of Otology and Neurotology at Massachusetts Eye and Ear and a professor of otolaryngology at Harvard Medical School. Dr McKenna holds an MD from the University of Southern California School of Medicine, completed his otolaryngology residency at Harvard Medical School, and his fellowship in neurotology and skull base surgery at the House Ear Clinic.

Last modified: November 01, 2021